

PATENT Docket No. 441472000100

### DECLARATION FOR UTILITY PATENT APPLICATION

## AS A BELOW-NAMED INVENTOR, I HEREBY DECLARE THAT:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled: TOXICITY TYPING USING EMBRYOID BODIES, the specification of which is attached hereto unless the following box is checked:

was filed on December 8, 1999 as United States Application Serial No. 09/457,931.

I HEREBY STATE THAT I HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE.

I acknowledge the duty to disclose information which is material to the patentability as defined in 37 C.F.R. § 1.56.

Thereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

Application No.	County et (day/rochth/year)	Prioniva	ila mec.
		□Yes	□No

I hereby claim benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Abotcaton sena No	
60/111,640	12/09/98

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application Separno	Rime Pate   Status		
	□ Patente	4	□Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date

ame:

H. Raiph SNODGRASS

Residence;

2221 Armada Way, San Mateo, California 94403

Citizenship:

United States of America


Post Office Address:

Same as above



PTO/SB/96 (10-92)

CERTIFICATE UNDER 37 C.F.R. § 3.73(b)			ER 37 C.F.R. § 3.73(b)		Docket No. 441472000100		
In the application of:  Serial No.:  O9/457,931  Filed:  December 8, 1999  For:  TOXICITY TYPING USING EMBRYOID BODIES							
Vist iden	aGen, It tified ab	nc., a corport love by virtue	ation, certifies that it is the assigne of either:	e of the entire right, t	itle and interest in the patent application		
A.	X	An assign copy there	ment from the inventor(s) of the part of is attached.	atent application identi	fied above. The assignment for which a		
OF	<b>t</b>						
B.	ū	A chain of below:	title from the inventor(s) of the pate	ent application identifie	ed above, to the current assignee as shown		
	1.	From:					
		To: The docuπ attached.	nent was recorded in the Patent and	Trademark Office at Re	eel , Frame , or for which a copy thereof is		
	<b>2</b>	From: To: The docum attached.	nent was recorded in the Patcnt and 1	Frademark Office at Re	eel, Frame, or for which a copy thereof is		
	3.	From:	•				
		To: The docum attached.	ent was recorded in the Patent and T	rademark Office at Re	el, Frame, or for which a copy thereof is		
		Additional	documents in the chain of title are li	sted on a supplemental	sheet.		
		Copies of a	ssignments or other documents in th	e chain of title are attac	ched.		
The u	ndersign Jersigne	ned has revie d's knowledg	wed all the documents in the chain of and belief, title is in the assignee in	of title of the patent app dentified above.	olication identified above and, to the best		
The u	ndersign	aed (whose ti	tle is supplied below) is empowered	to sign this certificate	on behalf of the assignee.		
I here and b and th and th	by declar elief are te like so at such	ere that all state believed to be made, are re	atements made herein of my own kn	nowledge are true, and ents are made with the	that all statements made on information knowledge that willful false statements,		
Dated	: <u> </u>	<u>cy 12,</u>	Do	Name: H. R Title: Presid	Alph SNODGRASS dent and Chief Executive Officer		





#### ASSIGNMENT SOLE

THIS ASSIGNMENT, by H. Ralph SNODGRASS (hereinafter referred to as the assignor), residing at 2221 Armada Way, San Mateo, California 94403, witnesseth:

WHEREAS, said assignor has invented certain new and useful improvements in TOXICITY TYPING USING EMBRYOID BODIES, set forth in an application for Letters Patent of the United States, having an oath or declaration executed on even date herewith; bearing Serial No. 09/457,931 and filed on December 8, 1999; and

WHEREAS, VistaGen, Inc., a corporation duly organized under and pursuant to the laws of California and having its principal place of business at 325 East Middlefield Road, Mountain View, California 94043 hereinafter referred to as the assignee is desirous of acquiring the entire right, title and interest in and to said inventions and said application for Letters Patent of the United States, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon:

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient consideration, the receipt of which is hereby acknowledged, said assignor has sold, assigned, transferred and set over, and by these presents does sell, assign, transfer and set over, unto said assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to the above-mentioned inventions, application for Letters Patent, and any and all Letters Patent or Patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all divisions, continuations and continuations-in-part of said application, or reissues or extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to he held and enjoyed by said assignee, for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted, as fully and entirely as the same would have been held and enjoyed by the assignor, had this sale and assignment not been made.

AND for the same consideration, said assignor hereby covenants and agrees to and with said assignee its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, said assignor is the sole and lawful owner of the entire right, title and interest in and to said inventions and the application for Letters Patent above-mentioned, and that the same are unencumbered and that said assignor has good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, said assignor hereby covenants and agrees to and with said assignee, its successors, legal representatives and assigns, that said assignor will, whenever counsel of said assignee, or the counsel of its successor, legal representatives and assigns, shall advise that any proceeding in connection with said inventions, or said application for Letters Patent, or any proceeding in connection with Letters Patent for said inventions in any country, including interference proceedings, is lawful and desirable, or that any division, continuation or continuation-in-part of any application for Letters Patent or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent for said inventions, without charge to said assignee, its successors, legal representatives and assigns, but at the cost and expense of said assignee, its successors, legal representatives and assigns.

AND said assignor hereby requests the Commissioner of Patents to issue said Letters Patent of the United States to said assignee as the assignee of said inventions and the Letters Patent to be issued thereon for the sole use of said assignee, its successors, legal representatives and assigns.

May 12,00

H. Ralph SNODGRASS

Docket No.: 441472000100







Applicant/Patentee: H. Ralph SNODGRASS

Scrial No./Patent No.: 09/457,931 Filed on/Issued: December 8, 1999

For: TOXICITY TYPING USING EMBRYOID BODIES

#### VERIFIED STATEMENT CLAIMING SMALL ENTITY STATUS 37 C.F.R. §§ 1.9(f) AND 1.27(e) — SMALL BUSINESS CONCERN

I hereby declare that I am

the owner of the small business concern identified below:

an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN: VistaGen, Inc.

ADDRESS OF CONCERN: 325 East Middlefield Road, Mountain View, California 94043

thereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 C.F.R. § 121.12, and produced in 37 C.F.R. § 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled TOXICITY TYPING USING EMBRYOID BODIES by inventor H. Ralph SNODGRASS, Ph.D. described in

- he specification filed herewith with title as listed above.
- It the application identified above.
- I the patent identified above.

If the rights held by the above identified business concern are not exclusive, each individual, concern or organization having rights in the invention must file separate verified statements averring to their status as small entities, and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 C.F.R. § 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 C.F.R. § 1.9(d), or a nonprofit organization under 37 C.F.R. § 1.9(e).

Each person, concern or organization having any rights in the invention is listed below;

- no such person, concern, or organization exists.
- ☐ each such person, concern or organization is listed below.

TOTAL TO	ADDRESS I
	☐ Individual
	☐ Small Business Concern
	☐ Nonprofit Organization

Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 C.F.R. § 1.27)

I acknowledge the duty to file, in this application or patent, notification or any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 C.F.R. § 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING:

H. Ralph Snodgrass

TITLE OF PERSON IF OTHER THAN OWNER: President and Chief Executive Officer


ADDRESS OF PERSON/SIGNING:

325 East Middleffeld Road, Mountain View, California 94043

DATE: May 12/00

PTO/SB/10 (10-92) pa-451611







Docket No. 441472000100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

H. Ralph SNODGRASS

Serial No.:

09/457,931

Filing Date:

December 8, 1999

For:

TOXICITY TYPING USING

EMBRYOID BODIES

Examiner: Not Yet Assigned

Group Art Unit: 1623

# PROSECUTION BY ASSIGNEE AND POWER OF ATTORNEY UNDER 37 C.F.R. § 3.71

Box Missing Parts
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Six:

VistaGen, Inc., the assignee of the entire right, title and interest in this patent application, under 37 C.F.R. § 3.71 hereby appoints:

Laurie A. Axford (Reg No. 35,053) Erwin J. Basinski (Reg No. 34,773) Frank P. Becking (Reg No. 42,309) Timothy J. Bortree (Reg No. 43,506) Tyler S. Brown (Reg No. 36,465) Jingming Cai (Reg No. P-44,579) Robert K. Cerpa (Reg No. 39,933) Thomas Chuang (Reg No. P-44,616) Steven X. Cui (Reg No. 44,637) Raj S. Davé (Reg No. 42,465) Carolyn A. Favorito (Reg No. 39,183) Debra J. Glaister (Reg No. 33,888) Franklin Y. Han (Reg No. 41,055) Peter Hsieh (Reg No. P-44,780) Richard D. Jordan (Reg No. 33,519) Kawai Lau (Reg No. 44,461) Richard H. Lilley (Reg No. 42,803)

Sanjay S. Bagade (Reg No. 42,280) Richard R. Batt (Reg No. 43,485) Kimberly A. Bolin (Reg No. 44,546) Barry E. Bretschneider (Reg No. 28,055) Nicholas Buffinger (Reg No. 39,124) Mark R. Carter (Reg No. 39,131) Peng Chen (Reg No. 43,543) Thomas E. Ciotti (Reg No. 21,013) Matthew M. D'Amore (Reg No. 42,457) Stephen C. Durant (Reg No. 31,506) Hector Gallegos (Reg No. 40,614) Kenneth R. Glick (Reg No. 28,612) Charles D. Holland (Reg No. 35,196) Madeline I. Johnston (Reg No. 36,174) Ararat Kapouytian (Reg No. 40,044) Elaine K. Lee (Reg No. 41,936) David C. Lundmark (Reg No. 42,815)



Lisa E. Marks (Reg No. 44,901) Gladys H. Monroy (Reg No. 32,430) Kate H. Murashige (Reg No. 29,959) William C. Revelos (Reg No. 42,101) Robert Saltzberg (Reg No. 36,910) Kevin R. Spivak (Reg No. 43,148) Thomas G. Wiseman (Reg No. 35,046) Karen R. Zachow (Reg No. 46,332)

Thomas D. Mays (Reg No. 34,524)
Philip A. Morin (Reg No. P-45,926)
Catherine M. Polizzi (Reg No. 40,130)
Paul J. Riley (Reg No. 38,596)
Debra A. Shetka (Reg No. 33,309)
E. Thomas Wheelock (Reg No. 28,825)
Frank Wu (Reg No. 41,386)

all of Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018, telephone (650) 813-5600, to prosecute this application and transact all matters in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorneys in accordance with the provisions of 37 C.F.R. § 3.71 provided that if any one of said attorneys or agents ceases being affiliated with the law firm of Morrison & Foerster as partner, employee or of counsel, such attorney's or agent's appointment as attorney or agent and all powers derived therefrom shall terminate on the date such attorney or agent ceases being so affiliated.

Please direct all written communications relative to this application to:

Gladys H. Monroy Morrison & Foerster LLP 755 Page Mill Road Palo Alto, California 94304-1018

Please direct all telephone communications to Gladys H. Monroy at (650) 813-5711.

VISTAGEN, INC. a California corporation

Dated: May 12,00

Name: H. Ralph Snodgrass

Title: President and Chief Executive Officer

Address: 325 East Middlefield Road Mountain View, CA 94043